Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle.
about
Treatment of recurrent hepatocellular carcinoma after liver transplantation.Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation.Evolving role of Sorafenib in the management of hepatocellular carcinoma.Multiple indications for everolimus after liver transplantation in current clinical practice.Activation of PI3K/AKT and MAPK pathway through a PDGFRβ-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma.CT perfusion of the liver: principles and applications in oncology.Major challenges limiting liver transplantation in the United States.Liver transplantation for hepatocellular carcinoma: outcomes and treatment options for recurrence.Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review.Decreased apoptosis in advanced-stage/high-grade hepatocellular carcinoma complicating chronic hepatitis C is mediated through the downregulation of p21 rasPractical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosisUse of Everolimus in Liver Transplantation: Recommendations From a Working Group.What is the role of adjuvant therapy after liver transplantation for hepatocellular carcinoma?Role of organ transplantation in the treatment of malignancies: hepatocellular carcinoma as the most common tumour treated with transplantation.The metabolic and toxicological considerations for mTOR inhibitors in the treatment of hepatocarcinoma.Cancer stem cells, microRNAs, and therapeutic strategies including natural products.Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge.Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition.Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation.Sorafenib use in the transplant setting.The role of sorafenib in downsizing hepatocellular carcinoma prior to liver transplantation and in treating tumor recurrence.Tailored long-term immunosuppressive regimen for adult liver transplant recipients with hepatocellular carcinoma.Sorafenib and a novel immune therapy in lung metastasis from hepatocellular carcinoma following hepatectomy: A case report.Liver transplantation: past, present and future.High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation.Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation.Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.Current Status of Hepatocellular Carcinoma Treatment in JapanEfficacy of Sorafenib for the Treatment of Post-Transplant Hepatocellular Carcinoma Recurrence
P2860
Q27692523-68880896-DF3E-49CD-858F-99A12C279761Q33408291-22C9100F-A724-46EB-86DE-41E09A55845EQ33779864-AB9D42EB-08CB-4DB1-A35A-71B48060CAFAQ33891730-3E71651B-809E-4C5B-9153-E1B9F84A05C3Q34200875-C0FDAADE-5DA1-47ED-BF34-514615714D04Q34681040-D5D893BA-60FA-460D-A40A-09388C2461ADQ35194675-8F287841-D0B7-4AEE-9CD1-77F6C995777BQ35779474-1EF45FCF-FBDA-4EA6-AD44-19EAA91B3538Q35818336-479B38BD-F368-4CA9-A297-A345614C598DQ36967501-D73C567F-4414-411A-945A-EF5855C04796Q37359379-FCA229C1-18F8-4144-83A0-156F02F6FE4CQ37605371-61BA07FA-CCA5-4391-B6DC-CB5707A707BBQ37895616-2A0805C6-8FF5-4845-A116-97E73A6FD793Q37928952-2F493BFD-2CE0-4D19-8742-5FD8AED024C2Q37950012-F436D6AD-95B8-4376-A72D-DA763697676EQ38023238-3A5DD3B6-F683-46B5-B81A-8006131E6E6BQ38045000-CF4738C7-679F-455D-9246-230456084549Q38155511-87B38F29-C503-4AA6-A055-1989C318AE24Q38174585-2BCFB68B-87BD-4468-83DC-33D42F0F470AQ38210270-7401CFF3-E62A-4B00-858D-A80DB6005C86Q38354102-C7BED7F5-EE6C-4FDE-93EB-0519098FA38BQ38438720-BB0A9194-8146-4FF9-AF33-C0E4FDCF4107Q39572032-C3E6E692-00EE-4A86-91BD-B8862CE058B3Q44195675-E7E687F2-0100-4084-B02D-32EAB0DDD292Q47279577-768FA3DF-20AA-480A-AADA-570CF172F0E1Q50767199-9709A0DB-7BF1-4176-B450-B3C00B3A60DEQ54558691-2FE7D51C-F8D0-43C9-858C-F754282A7E03Q57763108-83CDEE6B-72D4-4EDA-9769-3D895F262D1AQ58570352-3B512E4D-D6A7-460A-B5D6-1C598ACBBB67
P2860
Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Personalized molecular targete ...... ntation: a proof of principle.
@en
Personalized molecular targete ...... ntation: a proof of principle.
@nl
type
label
Personalized molecular targete ...... ntation: a proof of principle.
@en
Personalized molecular targete ...... ntation: a proof of principle.
@nl
prefLabel
Personalized molecular targete ...... ntation: a proof of principle.
@en
Personalized molecular targete ...... ntation: a proof of principle.
@nl
P50
P1476
Personalized molecular targete ...... antation: a proof of principle
@en
P2093
Alessandro Germini
Sara Toffanin
P304
P356
10.1016/J.JHEP.2010.01.025
P577
2010-03-04T00:00:00Z